Alzheimer’s disease is the most common form of dementia is not a natural part the aging process. According to the Alzheimer’s Foundation, we can expect that the prevalence of Alzheimer jump dramatically in 2050 between 11.3 to 16,000 cases. There is no FDA-approved treatments to stop or reverse progression of the disease. The cost of maintaining the current Alzheimer population is $ 100 billion per year.
Drugs approved for use currently treat only the symptoms of the disease, and only for a limited time. – Historically, researchers have been due to the high failure rate of promising Alzheimer’s treatments discouraged, said David Land, president of Medisyn Technologies. We use our technology to improve that success / failure ratio by much of the guesswork out of drug discovery. We have worked closely with Dr. Giulio Maria Pasinetti at Mount Sinai worked together the most promising functional signatures identify recite in a pipeline of new drug candidates.The tests show that compared to placebo, study NVA237 clearly the increased lung function in patients a rapid onset of the action at first doses, addition to improving exercise endurance. Said medicament for the approval for approval in the EU under the brand Seebr Breezhale NVA237 has a novel drug in which long-acting anti-muscarinic class. David Epstein, Division head of the Novartis Pharmaceuticals makes, said:. The survey reach GLOW1 announced its first endpoint.
Possess antimuscarinic lives. Suffer from nurture productive activity and active living, Novartis dates Shows Potential.
On the European Respiratory Society Amsterdam, Novartis presenting new Phase III dates and demonstrated potential of their new once-daily inhaling care for single suffering with a COPD, which to get get to a more active and productive lives.